Table 3 Hazard ratio and 95% confidence interval of overall survival according to treatment and incidence rate
Before matching | After matching | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | Incidence | Univariate | p-value | Multivariate | p-value | Univariate | p-value | Multivariate | p-value | ||
Treatment | |||||||||||
- AC | 126.44 | 1 | 1 | 1 | 1 | ||||||
- NAC | 147.643 | 1.08(0.82–1.42) | 0.596 | 1.05(0.79–1.39) | 0.733 | 1.13(0.81–1.58) | 0.480 | 0.83(0.49–1.40) | 0.477 | ||
Age group | |||||||||||
- <65 | 98.102 | 1 | 1 | 1 | 1 | ||||||
- ≥65 | 158.822 | 1.5(1.34–1.69) | < 0.001 | 1.49(1.32–1.68) | < 0.001 | 1.46(1.03–2.06) | 0.032 | 1.3(0.91–1.86) | 0.146 | ||
Gender | |||||||||||
- Female | 115.667 | 1 | 1 | 1 | 1 | ||||||
- Male | 131.678 | 1.12(0.98–1.28) | 0.085 | 1.17(1.03–1.34) | 0.019 | 1.58(1.09–2.3) | 0.015 | 1.59(1.09–2.33) | 0.016 | ||
CCI | |||||||||||
- <4 | 118.348 | 1 | 1 | 1 | 1 | ||||||
- ≥4 | 158.249 | 1.19(1.04–1.35) | 0.009 | 1.1(0.96–1.26) | 0.157 | 1.32(0.95–1.84) | 0.092 | 1.3(0.92–1.82) | 0.133 | ||
Chemotherapy duration | |||||||||||
- <2 months | 119.486 | 1 | 1 | 1 | 1 | ||||||
- ≥2 months | 159.953 | 1.31(0.91–1.87) | 0.142 | 1.26(0.91–1.75) | 0.167 | 1.3(0.93–1.81) | 0.130 | 1.51(0.9–2.54) | 0.119 | ||
Diagnosis year | |||||||||||
− 2004–2009 | 108.42 | 1 | 1 | 1 | 1 | ||||||
− 2010–2016 | 147.96 | 1.02(0.9–1.15) | 0.773 | 0.98(0.86–1.1) | 0.686 | 1.1(0.74–1.62) | 0.647 | 0.95(0.63–1.42) | 0.803 | ||